Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
Do inform your healthcare provider about any history of pancreatitis, gallbladder disease, or severe gastrointestinal disease (such as gastroparesis) before starting tirzepatide
& Umashanker, D
For users on compounded formulations , the ability to titrate in smaller increments (10mg to 11mg to 12mg rather than jumping straight to 12.5mg) is a significant advantage for heartburn-prone individuals
Jills MDLifespan Mold Protocol or as standalone support
